论文部分内容阅读
目的:观察头孢克洛缓释胶囊治疗急性细菌性上呼吸道感染患者的临床疗效。方法:对2013年4月-2014年4月我院收治的80例急性细菌性上呼吸道感染患者,随机分为对照组和实验组,每组各40例,对照组采用头孢氨苄胶囊治疗,实验组采用头孢克洛缓释胶囊治疗,比较两组疗效。结果:实验组有效率明显优于对照组,组间比较,差异具有统计学意义(P<0.05);实验组疗效满意率显著高于对照组,组间比较,差异具有统计学意义(P<0.05);实验组咳嗽消失时间、咽喉痛消失时间、发热消失时间、啰音消失时间,显著短于对照组,组间比较,差异具有统计学意义(P<0.05);实验组分离到86株病原菌,病原菌清除率为90.7%,显著高于对照组65株病原菌,清除率为84.6%,组间比较,差异具有统计学意义(P<0.05)。结论:急性细菌性上呼吸道感染患者采用头孢克洛缓释胶囊治疗效果理想。
Objective: To observe the clinical efficacy of cefaclor sustained-release capsules in the treatment of patients with acute bacterial upper respiratory tract infection. Methods: From April 2013 to April 2014, 80 patients with acute bacterial upper respiratory tract infection admitted to our hospital were randomly divided into control group and experimental group, 40 cases in each group. The control group was treated with cephalexin capsule. The experiment Group treated with cefaclor sustained-release capsules, the two groups were compared. Results: The effective rate of the experimental group was significantly better than that of the control group, the difference was statistically significant (P <0.05); the satisfaction rate of the experimental group was significantly higher than that of the control group, the difference was statistically significant (P < 0.05). The cough disappear time, the disappearance of sore throat, disappearance of fever and the disappearance of rales in the experimental group were significantly shorter than those in the control group (P <0.05). The experimental group isolated 86 strains Pathogenic bacteria, pathogenic bacteria clearance rate was 90.7%, significantly higher than the control group 65 pathogenic bacteria, clearance rate was 84.6%, between groups, the difference was statistically significant (P <0.05). Conclusion: Cefaclor sustained-release capsules in patients with acute bacterial upper respiratory tract infection are effective.